Recent Updates
Recently added Catalysts

SNX-5422

Phase 1

Cancer | Small molecule | Oncology |Pfizer, Inc.|Last Updated: May 28, 2012

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment44

FDA Designations

No designations recorded

Clinical trial landscape

SNX-5422 · 1 trial · 1 indication

Phase 1 1
NCT00506805Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor MalignanciesCancer
COMPLETED44 Analytics
PHASE1COMPLETED
Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
Cancer
NCT0050680544
Unlock trial analytics

Study Endpoints

Primary Endpoints

adverse events and other safety assessments
continuous

Secondary Endpoints

tumor response measured by X-rays or scans
after every 2 cycles
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Single ArmEXPERIMENTAL -

Interventions

NameTypeDescription
SNX-5422DRUGdose escalated, tablets every other day; undetermined duration until disease progression
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * \>18 years old * histologically confirmed solid tumor malignancy * refractory to available therapy or for which no therapy is available * adequate organ function Exclusion Criteria: * CNS malignancy * significant GI disease * at risk for prolonged QT interval

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Cancer 5 trials

CompanyTickerTrialsLead PhaseDrugs
GE Healthcare Technologies Inc.GEHC1PHASE1GEH200520/ GEH200521- Part A
Zimmer Biomet Holdings, Inc.ZBH1 - Undisclosed
Ascentage Pharma Group International Unsponsored ADRAAPG1PHASE1Olverembatinib
Unlock Competitive Intelligence

Frequently asked questions about SNX-5422

What is SNX-5422 used for?

SNX-5422 is an investigational small molecule being developed for the treatment of cancer. It is currently in Phase 1 clinical development and has been studied in patients with refractory solid tumor malignancies. The drug is not approved and remains under investigation.

Who makes SNX-5422?

SNX-5422 is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE on the New York Stock Exchange. The drug is an investigational oncology therapy that has completed a Phase 1 clinical trial.

What phase is SNX-5422 in?

SNX-5422 is in Phase 1 clinical development. It has completed one Phase 1 trial, and there are no active trials currently ongoing. The drug is investigational and has not been approved by regulatory authorities.

What clinical trials is SNX-5422 in?

SNX-5422 has been studied in one completed clinical trial, NCT00506805, titled 'Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies.' This Phase 1 trial enrolled 44 participants in the United States and was not randomized or blinded.

Is SNX-5422 FDA approved?

SNX-5422 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial for cancer. The drug remains in clinical development and has not received marketing approval.